Search results (578)
« Back to PublicationsLosartan and Prednisolone for Post-COVID Syndrome and Cardiac Inflammation: A Randomized, Double-Blind, Placebo-Controlled Trial
Journal article
Puntmann VO. et al, (2026), Nature Communications
Effect of Nipocalimab on IgG Responses to Vaccinations and Viral Infections in Patients with IgG Autoantibody–Mediated Diseases: Post Hoc Analyses of 3 Randomized, Placebo-Controlled Trials
Journal article
Yu F. et al, (2026), Human Vaccines & Immunotherapeutics
Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting
Journal article
Taylor PC. et al, (2026), Rheumatology and Therapy
ligning Approaches to Rheumatoid Arthritis Drug Development: An Expert Comparison of FDA and EMA Guidance
Journal article
Ciancio A. et al, (2026), The Lancet Rheumatology
Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies
Journal article
Baraliakos X. et al, (2026), Rheumatology and Therapy
Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence
Journal article
Tanaka Y. et al, (2026), Rheumatology and Therapy
Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Despite Prior Treatment With Advanced Therapies: Results From the Phase 2a DAISY-RA Study
Journal article
Taylor PC. et al, (2026), RMD Open
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease modifying antirheumatic drugs: 2025 update
Journal article
Smolen JS. et al, (2026), Annals of the Rheumatic Diseases
Do high rheumatoid factor levels impact response to certolizumab pegol in patients with inadequately controlled rheumatoid arthritis? A post hoc analysis of the phase IIIb REALISTIC trial.
Journal article
Smolen JS. et al, (2026), RMD Open, 12
Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.
Journal article
Taylor PC. et al, (2026), RMD Open, 12
The positive perspective paradigm: proposal of a model to mitigate the impact of chronic inflammatory arthritis through comprehensive and early intervention
Journal article
Doumen M. et al, (2026), Annals of the Rheumatic Diseases
The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritis.
Journal article
Triaille C. et al, (2026), Lancet Rheumatol, 8, e66 - e73
The effect of the Janus kinase-1 inhibitor filgotinib in proinflammatory cytokine production by ex-vivo myeloid and synovial derived cells from rheumatoid arthritis patients. Comparison to upadacitinib, tofacitinib and baricitinib
Conference paper
Weston S. et al, (2026), RHEUMATOLOGY, 65
Cross-speciality collaborative care in complex immune-mediated inflammatory diseases: treating the person living with the condition.
Journal article
Taylor PC. et al, (2025), BMC Med, 23
The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritis
Journal article
Triaille C. et al, (2025), Lancet Rheumatology